Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Reversibility of acrocyanosis and improvement of capillaroscopic pattern in a patient with polycythemia vera treated with ruxolitinib: a case report.
Blood Res
January 2025
Department of Rheumatology of Lucania - UOSD of Rheumatology, "Madonna Delle Grazie" Hospital, Matera, Italy.
This case report describes the clinical course of a 78-year-old patient diagnosed with polycythemia vera (PV), who presented with pronounced acrocyanosis of the hands in 2021. The patient was treated with hydroxyurea (oncocarbide), and nailfold capillaroscopy revealed an "abnormal pattern" characterized by pronounced architectural disarray and capillary tortuosity, which is uncommon in patients with myeloproliferative neoplasms (MPNs). In 2023, owing to suboptimal symptom management and hematological side effects, the treatment was switched to ruxolitinib, which led to significant clinical improvements by 2024, including near-complete resolution of acrocyanosis and substantial improvement in capillaroscopic abnormalities, with only residual capillary tortuosity noted.
View Article and Find Full Text PDFImproving the management of polycythemia vera patients eligible for cytoreduction: report of a multidisciplinary advisory board.
Curr Med Res Opin
January 2025
Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.
Introduction: The management of patients with Polycythemia Vera (PV) traditionally includes low-dose aspirin, phlebotomy, and cytoreductive therapy for high-risk individuals. Recent evidence suggests that cytoreductive treatment may be warranted for patients with additional risk factors beyond the traditional criteria of a history of thrombosis and age over 60 years. Introducing new therapeutic agents, including ropeginterferon alfa-2b and ruxolitinib, enables a more personalized treatment approach tailored to individual patient characteristics.
View Article and Find Full Text PDFPrevalence and predictive factors of testosterone-induced erythrocytosis: a retrospective single center study.
Front Endocrinol (Lausanne)
January 2025
Department of Internal Medicine, Division of Endocrinology, Diabetes and Clinical Nutrition, Luzerner Kantonsspital, Lucerne, Switzerland.
Aim: This study analyzes the prevalence and predictive factors of testosterone-induced erythrocytosis (TIE) in patients receiving testosterone replacement therapy (TRT).
Methods: Retrospective single-center observational study.
Results: 247 patients were included; median age was 47.
Associations Between Blood Hemoglobin Concentrations and Cardiometabolic Risk in Middle-Aged Women.
Womens Health Rep (New Rochelle)
January 2025
Department of Preventive Medicine, School of Medicine, Hyogo Medical University, Nishinomiya, Japan.
Objective: Patients with polycythemia have a high risk of thrombo-atherosclerotic diseases. However, it remains to be clarified whether a high blood hemoglobin level is related to cardiometabolic risk in women.
Methods: The overall subjects were 18,410 middle-aged women who had received health checkup examinations at their workplaces.
Correction: Hemorrhagic Stroke in a 24-Year-Old Male With Polycythemia Vera: A Case Report and Literature Review.
Cureus
January 2025
Neurology, St. Luke's Medical Center, Quezon City, PHL.
[This corrects the article DOI: 10.7759/cureus.76294.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!